Somboon VongterapakSoontaree NakasatienMonta SuppanichChanika SurasingchaidetMayura TepkasetkulBoonsong OngphiphadhanakulThep HimathongkamWinai DahlanTawee AnuntakulnateeWorawit KittipoomChattip TamwiwatPongamorn BunnagRajata RajatanavinTheptarin General HospitalChulalongkorn UniversityMahidol University2018-07-042018-07-041998-09-01Journal of the Medical Association of Thailand. Vol.81, No.9 (1998), 670-680012522082-s2.0-2442563861https://repository.li.mahidol.ac.th/handle/123456789/18493In a randomized, double-blind, placebo-controlled study, we investigated in normotensive type 2 diabetics with microalburninuria the effect of ramipril, an ACE inhibitor, on urine albumin excretion and serum lipids. A total of 1,882 patients were screened for urine microalbumin consecutively by dipstick test, Rapi Tex®-Albumin test and RIA. The final 28 normotensive and microalbuminuric patients were assigned to receive either ramipril (1.25 mg/d, n=16) or placebo (n=12) for 12 weeks. Throughout the study, both groups had no changes in blood pressure, fasting plasma glucose, HbA1C, serum creatinine and electrolytes and no difference in creatinine clearance. At week 12 only the placebo group showed the significant increment of urine albumin excretion and triacylglycerol (30.6±38.3 to 39.0±19.7 and 167±64 to 208±77 mg/dl, respectively) but the decrement of HDL-cholesterol (46±16 to 35±6 mg/dl). During a 3 month period, increased urine albumin excretion was observed in normotensive type 2 diabetes with microalbuminuria who received only placebo. We conclude that ramipril may arrest the progression of albumin excretion and had favorable effects on serum lipids. Ramipril was safe and well-tolerated without untoward side effects during the study period.Mahidol UniversityMedicineArticleSCOPUS